This article is more than 5 years old. Information may no longer be current.

Spark Therapeutics reports $32.6 million loss in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Spark Therapeutics reported a net loss of $32.6 million, or $1.07 per basic and diluted share, in the third quarter compared with a net loss of $16.9 million, or $0.70 per basic and diluted share, in the third quarter of 2015, according to a company press release.

Revenue was reported at $1.3 million, which the company attributed to a collaboration with Pfizer. The same amount was reported in the third quarter of 2015.

Research and development expenses were up by $10.6 million to $22.4 million compared with the third quarter of last year. General and administrative expenses were $12 million compared with $6.5 million a year ago.